

## Company Overview

Agentix Biopharma is a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. GPCRs are considered the largest family of proven therapeutic targets. To date there are over 134 drugs approved in the United States or the European Union which target GPCRs generating several billion dollars annually in revenues for pharmaceutical companies.[1]

Agentix Biopharma has developed partnerships with leading academic and research institutions. Agentix Biopharma has exclusively licensed patented, synthetically-derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. Agentix Biopharma is advancing these therapeutic product candidates in clinical trials.

[1] Sriram, K. & Insel, P., "G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?", *Molecular Pharmacology*, 93:251–258, April 2018.

## Stock Overview

Symbol	AGTX
Exchange	OTCPink
Market Cap	95.22m
Last Price	\$3.00
52-Week Range	\$1.01 - \$5.00

08/24/2020 03:54 PM EDT

## Investor Relations

[ir@agentixcorp.com](mailto:ir@agentixcorp.com)

## Management Team

### Rudy Mazzocchi

CEO, President and Chairman of the Board

### Martin Schroeder

Chief Scientific Officer

### Salman Hoda

SVP Portfolio & Business Development

### Mike Winterhalter

Secretary and Treasurer

### David Fiene

Controller

## Agentix Corp.

32932 Pacific Coast Highway  
Dana Point, CA 92629

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.